Biomarkers Suggest Black and Hispanic People Less Likely to Have Amyloid
To some, the findings suggest that non-AD pathologies, driven by other comorbidities, might contribute to cognitive decline in these populations.
NEWS
AI to Spot ARIA? FDA Says Yes
The commercial software icobrain aria sharpened radiologists’ ability to accurately detect ARIA-E and ARIA-H. The FDA approved the technology for clinical use November 7.
Fully Loaded: Secondary Prevention Studies of Lecanemab, Donanemab
In Madrid, researchers touted the benefits of plasma prescreening and showed baseline data on these early AD populations. Meanwhile, remternetug has begun Phase 3.
Tau Modification Drugs Take a Hit with Negative Trial
Lilly’s Phase 2 trial of its O-GlcNAcase inhibitor ceperognastat failed to meet clinical endpoints. The drug’s adverse events suggest potential off-target effects.
Finally, Therapeutic Antibodies Start to Reduce Tangles
Bepranemab results bolster hopes for antibodies targeting tau’s middle section. Whether tangle clearance will improve clinical outcomes remains unclear.
Leqembi: Side Effects No Worse in Clinical Use Than They Were in Trial
ARIA rates have been the same or lower than in the Phase 3 trial. About 9,000 people are being treated in the U.S., half as many in Japan. EMA reverses course, recommending approval.
Donanemab: Small Tweak in Titration, Big Gain in Safety?
By starting at a low dose and upping it stepwise for four months, scientists nearly halved the risk of ARIA while preserving plaque clearance.
Trontinemab Data Strengthen Hope for Brain Shuttles
Trontinemab swooped into the brain and removed amyloid efficiently, while causing few cases of ARIA. One person with cerebrovascular pathology died.
SPOTLIGHT
From Madrid, News on Anti-Amyloid and Anti-Tau Immunotherapy
At an airport hotel outside of Madrid, researchers hunkered down for the better part of a week to trade news about clinical trials for Alzheimer’s disease. The field is watching the rollout for lecanemab and donanemab with bated breath, tweaking administration, debating appropriate use, and hoping for no more deaths. As the rollout picks up speed, European regulators reversed their earlier rejection of lecanemab, and this week issued a thumbs up. Meanwhile, brain shuttle versions are on the horizon, led by trontinemab. Tau as a target is beginning to yield to mid-region antibodies, though OGA inhibition in its current form appears too toxic.
Join The Conversation
Professional Resources
New in last 7 days
-
Grants
- New Items: 7
- Total Items: 280
-
Jobs
- New Items: 1
- Total Items: 32
-
Conference Calendar
- Total Items: 88
- Member Directory
Latest Comments